[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Saint Vincent's Hospital, Korea\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":208},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,46,72,99,128,157,184],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":30,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100596451","comparison-of-intensive-versus-standard-care--education-for-dyslipidemia-in-hypertension-and-diabetes-patients-100596451",false,"NCT07045623","Comparison of Intensive Versus Standard Care & Education for Dyslipidemia in Hypertension and Diabetes Patients","Inclusion Criteria:\n\n* Patients registered in the Hanam City Hypertension and Diabetes Program\n* Adults aged 30 to 80 years\n* Individuals who have provided written informed consent to participate in the study\n\nExclusion Criteria:\n\n* Chronic kidney disease stage 4 or higher (eGFR \\\u003C30 mL\u002Fmin\u002F1.73m²)\n* Patients with liver cirrhosis or severe liver disease\n* Patients with a history of acute coronary syndrome within the past 6 months\n* Pregnant or breastfeeding women • Individuals with psychiatric disorders that may affect study participation","ALL","30 Years","80 Years",{"count":19,"type":20},348,"ESTIMATED","INTERVENTIONAL",[23],"NA","The prevalence of dyslipidemia is high among patients with hypertension and diabetes mellitus, which increases the risk of cardiovascular disease. However, many patients lack awareness and adherence to treatment and lifestyle modifications. Therefore, a more structured and intensive approach to management and education is required.\n\nThis study aims to implement intensive dyslipidemia management and education for patients registered at the Hanam City Hypertension and Diabetes Education Center and evaluate changes in blood lipid levels accordingly. Additionally, the study will analyze the impact of intensive education on patients' quality of life, health behaviors, and treatment adherence, ultimately contributing to the development of effective management strategies.",[26,27,28,29],"Hypertension","Diabetes Mellitus","Dyslipidemia","Primary Prevention",[31,32,28],"Primary prevention","Chronic disease","RECRUITING","2025-06-22",{"date":36,"type":37},"2025-07-01","ACTUAL",{"date":39,"type":37},"2025-04-01",{"date":41,"type":20},"2026-06-30",{"name":43,"class":44},"Saint Vincent's Hospital, Korea","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":15,"minAge":54,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":21,"phases":57,"briefSummary":59,"conditions":60,"keywords":63,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":45},"100530381","phase-4-clinical-comparison-of-low-dose-rosuvastatin-plus-ezetimibe-combination-therapy-and-high-dose-rosuvastatin-monotherapy-in-patients-with-minimal-to-intermediate-coronary-artery-disease-without-percutaneous-coronary-intervention-100530381","NCT06186037","Clinical Comparison of Low-dose Rosuvastatin Plus Ezetimibe Combination Therapy and High-dose Rosuvastatin Monotherapy in Patients With Minimal to Intermediate Coronary Artery Disease Without Percutaneous Coronary Intervention","Clinical Comparison of Low-dose Rosuvastatin Plus Ezetimibe Combination Therapy and High-dose Rosuvastatin Monotherapy in Patients With Minimal to Intermediate Coronary Artery Disease Without Percutaneous Coronary Intervention : A Prospective, Multicenter, Randomized, Open-label Trial","ALMIGHTY","Inclusion Criteria:\n\n1. Male and female adjusts (19 or older)\n2. Patients with suspected stable angina pectoris without coronary artery interventions, who showed a minimal to intermediate coronary artery diseases (a stenosis of 10 to 70% diameter as per QCA) in at least one natural coronary artery in coronary artery angiography or coronary artery CT.\n3. Patients who gave their informed consent themselves in writing.\n4. Patients who were treated with statin or lipid-lowering agents may participate in the study by changing the existing medicines.\n\nExclusion Criteria:\n\n1. Patients with an intermediate (\\>30%) lesion on the left main coronary artery.\n2. Patients diagnosed with acute coronary artery diseases (STEMI, NSTEMI, Unstable angina)\n3. Patients who received percutaneous coronary intervention\n4. Patients who have been diagnosed with stroke, transitory ischemic attack, and peripheral artery diseases.\n5. Patients diagnosed with variant myocardial infarction\n6. Patients with severe liver diseases or lung diseases and\u002For malignant tumor with life expectancy of less than 3 years\n7. Patients with severe valvular heart disease\n8. Patients who are hypersensitive or prohibited from using the active substance (Ezetimibe or Rosuvastatin) of the study medicines\n9. Patients with cardiogenic shock\n10. Pregnant women or women who are planning to get pregnant\n11. Patients who are receiving hemodialysis or peritoneal dialysis or received renal transplantation due to end-stage renal failure\n12. Patients who participated in other clinical studies within the past three months (except for non-interventional observation studies)","19 Years",{"count":56,"type":20},6356,[58],"PHASE4","\\[Purpose of the Clinical Study\\]:The purpose of this study is to conduct a clinical comparison of low-dose rosuvastatin plus ezetimibe combination therapy and high-dose rosuvastatin monotherapy in patients with minimal to intermediate coronary artery disease without percutaneous coronary intervention to confirm non-inferiority in the reduction of key cardiovascular events.\n\n\\[Hypothesis\\]:In patients who have not undergone percutaneous coronary intervention for minimal to moderate coronary artery disease, low-dose rosuvastatin and ezetimibe combination therapy are non-inferior in terms of reducing major cardiovascular events compared to high-dose rosuvastatin monotherapy.",[61,62,29],"Coronary Artery Disease","Dyslipidemias",[61,62,29],"2025-06-19",{"date":66,"type":37},"2025-06-25",{"date":68,"type":37},"2024-02-01",{"date":70,"type":20},"2029-02-28",{"name":43,"class":44},{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":15,"minAge":54,"maxAge":4,"enrollmentInfo":80,"targetDuration":4,"studyType":21,"phases":82,"briefSummary":83,"conditions":84,"keywords":86,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":45},"100516316","comparison-of-provisional-1-stent-strategy-with-deb-versus-planned-2-stent-strategy-in-coronary-bifurcation-lesions-100516316","NCT06002932","Comparison of PROVISIONal 1-stent Strategy with DEB Versus Planned 2-stent Strategy in Coronary Bifurcation Lesions.","Comparison of PROVISIONal 1-stent Strategy with Drug-Eluting Balloon Versus Planned 2-stent Strategy in Patients with Non-LM Coronary True-Bifurcation Lesions.","PROVISIONDEB","Inclusion Criteria:\n\n① 19+ years old\n\n② Patients with the following lesions and clinical factors. 2-1. The lesion factor: Visually confirmed diameter of the 2.25-2.75 mm in branched vessels, where the main blood vessel's diameter is at least 2.5 mm; the lesion at the branched vessels is of a Medina classification (1,1,1), (1,0,1), or (0,1,1), with a true bifurcation; a de novo lesion.\n\n2-2 Clinical factors: Stable angina pectoris, unstable angina pectoris, or myocardial infarction with an elevated non-ST segment, all at least 24 hours after their last treatment.\n\n③ Patients who understood the definitions of the test group and the control group and the risks involved in the treatment, and with voluntary, informed consent to participate in the study, as provided either by the patient or their legal representatives.\n\nExclusion Criteria:\n\n* Patients with myocardial infarction involving an elevated ST segment, or patients with an LM coronary true-bifurcation lesion.\n\n  * Patients who are ruled out by the treatment provider because the 2-stent strategy was deemed unsuitable to the patient due to a clinical condition.\n\n    * A patient with aspirin or P2Y12 inhibitors (ticagrelor or clopidogrel) contraindications.\n\n      * A patient who experienced psychogenic shock at the time of admission, or showed severe left ventricle insufficiency (where the left ventricle ejection fraction is less than 30%.)\n\n        * A patient who requires prolonged anti-coagulative treatment (warfarin or a new oral anti-coagulant \\[NOAC\\])\n\n          * A patient who is currently hemorrhagic, or has a high risk of major hemorrhage (active peptic ulcer, GI lesions with high hemorrhagic risks, malicious tumors with a high risk of hemorrhage) ⑦ A patient with a history of intra-cerebral hemorrhage or intra-cerebral aneurysm.\n\n            * A patient for whom surgery that requires antiplatelet treatment intervention is scheduled within the next six months.\n\n              ⑨ A patient with severe hepatic diseases (abdominal effusion) Platelet count at less than 80,000 cells\u002Fmm3 Hgb count at less than 10 g\u002FdL\n\n              ⑩ A patient who appears to be at risk of bradycardia (a patient with an insufficiency of the said function, or a patient without a permanent pacemaker despite a grade 2 or higher atrioventricular block).\n\n              ⑪ A patient who tested positive in a pregnancy test, or is currently breastfeeding\n\n              ⑫ A patient with less than one year of remaining life expectancy due to comorbidity (based on the medical judgment of the investigator).\n\n              ⑬ A patient who is already participating in another randomized clinical study for other medicines or medical devices, where the primary end point has not been reached.\n\n              ⑭ A patient who did not sign her informed consent form, or could not be traced in the long-term.",{"count":81,"type":20},750,[23],"\\[The Purpose of the Clinical Study\\] The purpose of this randomized comparison study is to compare the 1-stent strategy with a drug-eluting balloon and the 2-stent strategy in patients with non-LM coronary true-bifurcation lesions.\n\n\\[Hypothesis\\] In this study, the researchers intend to verify the hypothesis that the 1-stent strategy with a drug-eluting balloon is non-inferior to the 2-stent strategy in terms of target lesion failures (cardiac death, target vessel MI, or target vessel revascularization).",[61,85],"Ischemic Heart Disease",[87,88,89,90],"coronary artery disease","percutaneous coronary intervention","coronary bifurcation lesion","strategy","2025-02-05",{"date":93,"type":37},"2025-02-10",{"date":95,"type":37},"2023-09-08",{"date":97,"type":20},"2028-12-31",{"name":43,"class":44},{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":4,"eligibilityCriteria":105,"healthyVolunteers":11,"sex":15,"minAge":106,"maxAge":107,"enrollmentInfo":108,"targetDuration":4,"studyType":21,"phases":110,"briefSummary":111,"conditions":112,"keywords":4,"overallStatus":119,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":4},"100574249","effects-of-3-month-melatonin-treatment-on-regional-cerebellar-structure-and-blood-biomarkers-in-alzheimers-disease-spectrum-100574249","NCT06756828","Effects of 3-Month Melatonin Treatment on Regional Cerebellar Structure and Blood Biomarkers in Alzheimer's Disease Spectrum","Study on Regional Structural Changes in the Cerebellum Associated with Blood Biomarkers, Cognitive Decline, and Physical Performance in Alzheimer's Spectrum Patients Following a 3-Month Melatonin Treatment Using Digital Health Technology","Inclusion Criteria:\n\n* Male and female participants aged 60 to 90 years\n* Individuals presenting with cognitive impairment as their chief complaint at the Department of Psychiatry, St. Vincent's Hospital\n* Those capable of undergoing imaging studies, including Brain MRI and Amyloid PET CT\n* Individuals able to complete cognitive function tests, such as the Alzheimer's Disease Consortium test battery, K-MMSE, CDR, and GDS\n* Participants who can perform tests at the hospital's Smart Center, including the Short Physical Performance Battery and body composition analysis using direct segmental multi-frequency bioelectrical impedance analysis for sarcopenia\n* Individuals on acetylcholinesterase inhibitors (ACEi) or NMDA receptor antagonists who have maintained the same dosage and regimen for more than 3 months from the screening date.\n* Patients who are taking medications for cognitive function treatment other than acetylcholinesterase inhibitors and NMDA receptor antagonists (e.g., pregabalin, gabapentin, choline alfoscerate), as well as medications for chronic diseases such as antidepressants, antihypertensives, diabetes, hyperlipidemia, thyroid disorders, etc., must have maintained the same dosage and regimen for more than 1 month from the screening date.\n* Individuals with sufficient language proficiency to read and understand the informed consent document and respond to survey questionnaires\n\nExclusion Criteria:\n\n* Individuals with progressive mental or neurological disorders (including those with a history of psychotic disorders such as major depressive disorder, bipolar disorder, schizophrenia, schizoaffective disorder, schizophreniform disorder, or unspecified psychosis; patients currently experiencing major depressive disorder with psychotic symptoms; organic mental disorders; epilepsy or seizure disorders; patients currently suffering from eating disorders or obsessive-compulsive disorder).\n* Individuals with unstable or severe medical conditions.\n* Patients with severe snoring, REM sleep behavior disorder, or narcolepsy.\n* Illiterate individuals.\n* Individuals who, in the opinion of the investigator, are deemed unable to comply with the requirements of the study.\n* Patients currently taking sleeping pills within 2 weeks of the screening point.","60 Years","90 Years",{"count":109,"type":20},40,[23],"The goal of this clinical trial is to explore and verify the preventive effects of melatonin on the progression of Alzheimer's disease. The study aims to analyze the changes in blood biomarkers (phosphorylated tau, glial fibrillary acidic protein, neurofilament chain), various sleep-related subjective report questionnaire scores, physical performance, cognitive function scores and cerebellar volume change after three months of melatonin administration in patients with Alzheimer's-type mild cognitive impairment (MCI) accompanied by insomnia. The main questions it aims to answer are:\n\n1. Does melatonin administration alter the levels of blood biomarkers associated with Alzheimer's disease?\n2. What changes occur in sleep-related subjective report questionnaire scores and cognitive function scores following melatonin administration?\n3. Does melatonin administration effect on physical performance?\n4. Is there any relations between cognitive decline, phsycal performance and cerebellar volume change? We will compare the data collected before and after melatonin administration to determine its preventive effects on Alzheimer's disease progression.\n\nParticipants Will:\n\n1. Take melatonin every day for 3 months and Complete sleep-related subjective report questionnaires, neuropsychological assessments and physical performance test\n2. Visit the clinic at the initial visit and after 3 months for checkups and tests.\n3. Complete sleep-related subjective report questionnaires and neuropsychological assessments and physical performance test\n4. Provide blood samples for biomarker analysis.",[113,114,115,116,117,118],"Elderly","Alzheimer Disease","Melatonin","Cognitive Decline","Biomarker with Neurodegeneration Patients","Cerebellum","NOT_YET_RECRUITING","2024-12-23",{"date":122,"type":37},"2025-01-03",{"date":124,"type":20},"2025-01-15",{"date":126,"type":20},"2026-12-30",{"name":43,"class":44},{"id":129,"slug":130,"hasResults":11,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":134,"eligibilityCriteria":135,"healthyVolunteers":11,"sex":15,"minAge":136,"maxAge":4,"enrollmentInfo":137,"targetDuration":4,"studyType":21,"phases":139,"briefSummary":140,"conditions":141,"keywords":145,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":150,"startDateStruct":152,"completionDateStruct":154,"leadSponsor":156,"locationsCount":45},"100513880","verifying-remote-monitoring-effect-on-net-cardiovascular-outcome-remoteverify-rve-100513880","NCT05971225","Verifying Remote Monitoring Effect on Net Cardiovascular Outcome; RemoteVerify (RêVe)","Prospective Multicenter Observation Study on the Association Between Remote Monitoring and Clinical Outcome in Heart Failure Patients (Verifying Remote Monitoring Effect on Net Cardiovascular Outcome; RemoteVerify (RêVe))","ReVe","Inclusion Criteria:\n\n* consented heart failure patients (LVEF\\\u003C=40%) with Biotronik wireless monitoring capable ICD\u002FCRTs aged \\>20 years\n* patients who are new to remote monitoring\n\nExclusion Criteria:\n\n* For patients with a life expectancy of less than 6 months. If patient do not understand the contents of wireless monitoring or it is difficult to fill out the consent form due to cognitive decline.\n\nIf wireless monitoring is performed with a patient enrolled in another clinical trial which remote monitoring may affect the previous enrolled study.","20 Years",{"count":138,"type":20},450,[23],"This study investigates the impact and safety of wireless monitoring on the prognosis of heart failure patients with implanted pacemakers and defibrillators. It aims to examine the frequency of unplanned early hospital visits and the early diagnosis\u002Fintervention of disease exacerbation based on the presence or absence of wireless monitoring. Additionally, the study analyzes the influence of wireless monitoring on the patient's disease progression as well as satisfaction of the study participants.",[142,143,144],"Congestive Heart Failure","Defibrillators","Cardiac Resynchronization Therapy",[146,147,143,148],"remote monitoring","congestive heart failure","cardiac resynchronization therapy","2024-11-28",{"date":151,"type":37},"2024-12-03",{"date":153,"type":37},"2023-11-11",{"date":155,"type":20},"2027-04-30",{"name":43,"class":44},{"id":158,"slug":159,"hasResults":11,"nctId":160,"briefTitle":161,"officialTitle":162,"acronym":4,"eligibilityCriteria":163,"healthyVolunteers":11,"sex":164,"minAge":165,"maxAge":4,"enrollmentInfo":166,"targetDuration":168,"studyType":169,"phases":4,"briefSummary":170,"conditions":171,"keywords":173,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":176,"lastUpdatePostDateStruct":177,"startDateStruct":179,"completionDateStruct":181,"leadSponsor":183,"locationsCount":45},"100566554","study-on-water-vapor-thermal-therapy-100566554","NCT06656689","Study on Water Vapor Thermal Therapy","Prospective Observational Study on Water Vapor Thermal Therapy in Management of Patients With Benign Prostatic Hyperplasia (BPH)","Inclusion Criteria:\n\n* Age 50 or older\n* Prostate size between 30cc and 80cc as measured by transrectal ultrasound\n* Patients scheduled for Rezum surgery for BPH\n\nExclusion Criteria:\n\n* Suspected prostate cancer\n* Suspected urinary tract infection\n* Inability to complete follow-up\n* Patients who do not consent to participate in the study","MALE","50 Years",{"count":167,"type":20},300,"3 Months","OBSERVATIONAL","The goal of this observational study is to learn about the efficacy of Rezum water vapor thermal therapy in benign prostatic hyperplasia patients. The main question it aims to answer is:\n\n* Is Rezum an effective treatment?\n* Is Rezum safe?\n\nParticipants will be followed up for at least three months after the treatment to evaluate efficacy and safety.",[172],"Benign Prostatic Hyperplasia",[172,174,175],"Rezum","Water Vapor Thermal Therapy","2024-11-04",{"date":178,"type":37},"2024-11-06",{"date":180,"type":37},"2023-07-31",{"date":182,"type":20},"2028-10-31",{"name":43,"class":44},{"id":185,"slug":186,"hasResults":11,"nctId":187,"briefTitle":188,"officialTitle":189,"acronym":4,"eligibilityCriteria":190,"healthyVolunteers":11,"sex":15,"minAge":54,"maxAge":17,"enrollmentInfo":191,"targetDuration":4,"studyType":21,"phases":193,"briefSummary":194,"conditions":195,"keywords":197,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":200,"lastUpdatePostDateStruct":201,"startDateStruct":203,"completionDateStruct":205,"leadSponsor":207,"locationsCount":45},"100279682","the-effect-in-wedge-resection-and-ivbv-resection-of-the-liver-for-gallbladder-cancer-100279682","NCT02920554","The Effect in Wedge Resection and IVb\u002FV Resection of the Liver for Gallbladder Cancer","The Effect in Wedge Resection and IVb\u002FV Resection of the Liver for Gallbladder Cancer Operation: Prospective Randomized Controlled Trial","Inclusion Criteria:\n\n* Patients with T2 or T3 gallbladder cancer on preoperative CT exam\n* Patients who are pathologically diagnosed as T2 or T3 gallbladder cancer after initial simple cholecystectomy\n\nExclusion Criteria:\n\n* Peritoneal seeding or distant metastasis\n* Impossible to resect the cancer radically\n* Pathologically diagnosed to other malignancy such as adenosquamous carcinoma, sarcoma, etc.\n* R1 or R2 resection were pathologically diagnosed.",{"count":192,"type":20},88,[23],"The extent of hepatic resection for gallbladder cancer can be done from a wedge resection to 4b\u002F5 bisegmentectomy. This study aims to compare the recurrence rates and survival rates between wedge resection group and bisegmentectomy group. Patients with T2 or T3 gallbladder cancer on preoperative CT exam or patients who were pathologically diagnosed as T2 or T3 gallbladder cancer after initial simple cholecystectomy were enrolled. All patients are randomly assigned to wedge resection or bisegmentectomy group. Number of patients in each group is 44. Primary endpoint is recurrence-free-survival rates and overall survival rates.",[196],"Gallbladder Cancer",[198,199],"gallbladder cancer","bisegmentectomy","2024-05-20",{"date":202,"type":37},"2024-05-22",{"date":204,"type":4},"2014-07",{"date":206,"type":20},"2030-12",{"name":43,"class":44},""]